Wells Fargo & Company Altimmune, Inc. Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ALT
# of Institutions
190Shares Held
42.2MCall Options Held
1.05MPut Options Held
582K-
Black Rock Inc. New York, NY5.32MShares$36.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.91MShares$33.3 Million0.0% of portfolio
-
State Street Corp Boston, MA3.91MShares$26.5 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.22MShares$21.9 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$18.7 Million2.23% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $333M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...